We therefore decided to analyse long-term follow-up data from the first published randomised study of G-CSF administration in NHL patients (Pettengell et al, 1992) to determine whether the use of G-CSF and consequent increase in chemotherapy dose intensity will impact long-term survival, overall morbidity or the development of unexpected late complications. Here, CSF3 is linked to non-Hodgkin lymphoma.